The Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere) to treat people with certain ovarian cancers whose tumors produce too much of a protein called FR-α. The full approval was based on the results of a large, randomized trial called MIRASOL.
For women with harmful changes in the BRCA1 or BRCA2 gene, regular MRI scans and having surgery to remove ovaries and fallopian tubes (called bilateral salpingo-oophorectomy) appear to lower their chances of dying from breast and ovarian cancer, according to results from two studies.
A recent clinical trial showed that adding rusfertide to treatment for polycythemia vera reduced blood draws from nine in one year to less than one. The finding may improve the quality of life for people who manage the blood cancer with frequent blood draws.
Clinical Trials Information for Patients and Caregivers
Clinical trial participants are a vital part of cancer research and there are federal rules in place to help ensure the safety and ethics of clinical trials.
This phase 2 trial will test the effectiveness of combining nivolumab (Opdivo) and cabozantinib (Cabometyx) to treat people with melanoma or squamous cell head and neck cancer that has spread. This trial may help doctors learn if these drugs shrink or stabilize the cancer, and whether patients respond differently to the combination depending on certain biomarkers.
This clinical trial will compare two surgeries to see how well they work in reducing the risk of ovarian cancer. People with mutations in their BRCA1 gene will undergo surgery to either remove both their ovaries and fallopian tubes or just their fallopian tubes. Doctors want to see if removing only the fallopian tubes will be as effective at preventing ovarian cancer while preserving some ovarian function.
This phase 3 trial studies how well bupropion (Wellbutrin) works in reducing cancer-related fatigue in stage 1 to 3 breast cancer survivors. Bupropion is usually used to treat depression and help people quit smoking.
